Find an Article

Filter articles

Showing 11 to 20 of 790 results

Regimen patents in Japan: LCM failures and successes

Japan19-09-2023Takanori Abe

Examining a series of case studies, Takanori Abe of Abe & Partners provides an overview of lifecycle management failures and successes in regimen patents.

UK universities prove resilience during Horizon hiatus

UK14-09-2023Sarah Speight

Although UK research universities were going strong after Horizon funding was pulled, it could have been a different story had the scheme not been reinstated, finds Sarah Speight.

Is there a step between ‘inventive’ and ‘nonobviousness’?

EU, UK, US12-09-2023Jeffrey Lewis and Stuart Knight

Despite the shared language, there are tangible differences between the US, EU and UK standards, explain Jeffrey Lewis and Stuart Knight of Foley Hoag.

‘One of the most positive announcements since Brexit’: UK lawyers react to new Horizon funding deal

EU, UK07-09-2023Sarah Speight

The news that the UK will rejoin the €95.5 billion research fund has been met with widespread relief, but it’s a bittersweet story, finds Sarah Speight. Reaction from CMS, Arnold & Porter, Bird & Bird, HGF.

Femtech: from taboo to multibillion-dollar industry

International07-09-2023Liz Hockley

Technology is continuing to transform women’s healthcare and female inventors are driving the change—but more needs to be done to ensure they secure IP rights.

Everybody loses in the end: Billion-dollar government prizes won't improve on market incentives

US29-08-2023Andrei Iancu and David Kappos

Bernie Sanders’ plan to ‘delink’ the price of drugs from the cost of development ignores history, argue Andrei Iancu and David Kappos.

Axonics v Medtronic: Fed Circ addresses PTAB ‘errors’

US17-08-2023Blair Jacobs

A recent precedential case highlights the thorny issue of what constitutes a fair response to new claim constructions following an institution, says Blair Jacobs of McKool Smith.

One year on: The US Inflation Reduction Act

US15-08-2023Alice Valder Curran and Cullen Taylor

This week marks the first anniversary of its enactment but the US Inflation Reduction Act still poses questions for pharmaceutical companies, say Alice Valder Curran and Cullen Taylor of Hogan Lovells.

UPC: life sciences lead the momentum at new court

EU15-08-2023Antje Brambrink

Are we now seeing the power posed by the court as a litigation forum, asks Antje Brambrink of Finnegan.

Cannabis and IP: Nurturing innovation in Brazil’s life sciences industry

Brazil03-08-2023Priscila Kashiwabara and Luan Scalzitti

A reticent patent office and complex legal picture make getting IP protection of treatments based on the lucrative plant tricky, explain Priscila Kashiwabara and Luan Scalzitti of Kasznar Leonardos.

Showing 11 to 20 of 790 results